Core Viewpoint - Arcturus Therapeutics (ARCT) shows significant upside potential based on Wall Street analysts' short-term price targets, with a mean target of $65.43 indicating a 503.6% increase from the current price of $10.84 [1] Price Targets and Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $34.14, indicating variability among analysts. The lowest estimate of $44 suggests a 305.9% increase, while the highest estimate predicts a surge of 1191.5% to $140 [2] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about ARCT's earnings prospects, as indicated by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 28.3% over the last 30 days, with four estimates moving higher and no negative revisions [11][12] - ARCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in analysts' price targets [3][7][10] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Core Viewpoint - Dream Finders Homes Inc. (DFH) has shown a significant price increase of 11.1% over the past four weeks, with a mean price target of $29.50 indicating a potential upside of 26.8% from the current price of $23.26 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.44, where the lowest estimate is $26 (an 11.8% increase) and the highest is $34.50 (a 48.3% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about DFH's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 2.9% increase in the Zacks Consensus Estimate for the current year [11][12] - DFH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' price targets can often be overly optimistic due to business incentives [3][8][10]

Core Viewpoint - Enanta Pharmaceuticals (ENTA) has seen a 5.1% increase in share price over the past four weeks, closing at $5.18, with a mean price target of $15 indicating a potential upside of 189.6% according to Wall Street analysts [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $7.27, indicating variability among analysts; the lowest estimate suggests a 3.5% decline, while the highest predicts a 344% increase to $23 [2][9]. - Analysts' price targets are often viewed with skepticism due to historical inaccuracies, as they may not reliably indicate future stock price movements [7][10]. - A low standard deviation in price targets suggests a strong consensus among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising ENTA's earnings estimates upward, which correlates with potential stock price increases; the Zacks Consensus Estimate has risen by 26.2% over the past 30 days [4][12]. - ENTA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a solid potential upside [13].

Core Viewpoint - Janus International Group, Inc. (JBI) has shown a significant price increase of 35.6% over the past four weeks, with a mean price target of $10.80 indicating a potential upside of 27.1% from the current price of $8.50 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $3.11, indicating variability among analysts; the lowest estimate is $7 (17.7% decline), while the highest is $14 (64.7% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, although it does not guarantee the stock will reach the average target [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about JBI's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 35.4% over the past month, with no negative revisions reported [12] - JBI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]

Group 1 - Edgewise Therapeutics, Inc. (EWTX) shares have increased by 14.4% over the past four weeks, closing at $14.89, with a mean price target of $40.90 indicating a potential upside of 174.7% [1] - The average of 10 short-term price targets ranges from a low of $14 to a high of $52, with a standard deviation of $14.28, suggesting variability in analyst estimates [2] - Analysts show strong agreement on EWTX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for EWTX's current year earnings has increased by 6.8% over the past month, with four estimates rising and one falling [12] - EWTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide a directional guide for price movement [13]

Core Viewpoint - BridgeBio Pharma (BBIO) shows potential for significant upside, with a mean price target of $58.47 indicating a 63.9% increase from its current price of $35.68 [1] Price Targets and Estimates - The mean estimate consists of 17 short-term price targets with a standard deviation of $12.24, suggesting variability in analyst predictions [2] - The lowest estimate is $37, indicating a 3.7% increase, while the highest estimate is $95, suggesting a potential surge of 166.3% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism regarding BBIO's earnings, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 16.6% over the past month, with eight estimates increasing and one decreasing [12] - BBIO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Core Viewpoint - Ardent Health Partners, Inc. (ARDT) has shown a significant price increase of 19.4% over the past four weeks, with analysts projecting a mean price target of $20.25, indicating a potential upside of 36.6% from the current price of $14.83 [1] Price Targets and Analyst Consensus - The average price target for ARDT is based on 10 short-term estimates, ranging from a low of $15.50 to a high of $24, with a standard deviation of $2.80, suggesting a variability in analyst predictions [2] - The lowest estimate indicates a 4.5% increase, while the highest suggests a 61.8% upside, highlighting the range of potential outcomes [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ARDT's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.7%, with two estimates moving higher and one lower [12] - ARDT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13]

Group 1: Stock Performance and Price Targets - Tectonic Therapeutic, Inc. (TECX) closed at $20.71, with a 15.9% gain over the past four weeks, indicating potential upside based on Wall Street analysts' short-term price targets [1] - The mean price target of $74.25 suggests a 258.5% upside potential, with the lowest estimate at $51 (146.3% increase) and the highest at $101 (387.7% increase) [2] - The standard deviation of $20.71 indicates variability in analysts' estimates, with a smaller standard deviation suggesting greater agreement among analysts [2][9] Group 2: Analyst Insights and Earnings Estimates - Analysts show strong agreement on TECX's ability to report better earnings than previously predicted, which supports the view of potential upside [4] - A positive trend in earnings estimate revisions has a strong correlation with near-term stock price movements, indicating a legitimate reason to expect an upside [11] - The Zacks Consensus Estimate for the current year has increased by 9.8%, with one estimate moving higher and no negative revisions in the last 30 days [12] Group 3: Zacks Rank and Investment Considerations - TECX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [13]

Treace Medical Concepts (TMCI) closed the last trading session at $7.20, gaining 6.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.16 indicates a 41.1% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $2.16. While the lowest estimate of $8 indicates an 11.1% increase from the current price level, the most optimistic ana ...

Core Viewpoint - NewAmsterdam Pharma Company N.V. (NAMS) has shown a significant price increase of 21.5% over the past four weeks, with a mean price target of $42.71 indicating a potential upside of 132.5% from the current price of $18.37 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from a low of $37 to a high of $52, with a standard deviation of $5.28, suggesting a high degree of agreement among analysts [2] - The lowest estimate indicates a potential increase of 101.4%, while the most optimistic estimate suggests an upside of 183.1% [2] - Analysts' price targets should be approached with caution, as empirical research indicates they often mislead investors rather than provide accurate guidance [7][10] Earnings Estimates and Market Sentiment - Analysts are optimistic about NAMS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 3.8% rise in the Zacks Consensus Estimate for the current year [12] - NAMS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, further supporting its potential upside [13]